Brown Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brown Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$520K	Buy	+9,087	New	+$498K	﹤0.01%	1127
2018 Q1	–	Sell	-7,492	Closed	-$668K	–	1184
2017 Q4	$668K	Sell	7,492 -143	-2%	-$12.4K	﹤0.01%	792
2017 Q3	$711K	Sell	7,635 -194	-2%	-$17.1K	﹤0.01%	746
2017 Q2	$711K	Hold	7,829	–	–	﹤0.01%	759
2017 Q1	$687K	Hold	7,829	–	–	﹤0.01%	723
2016 Q4	$648K	Buy	7,829 +1,329	+20%	+$114K	﹤0.01%	728
2016 Q3	$601K	Sell	6,500 -7,087	-52%	-$667K	﹤0.01%	718
2016 Q2	$1.06M	Buy	13,587 +8,196	+152%	+$697K	﹤0.01%	591
2016 Q1	$445K	Buy	5,391 +940	+21%	+$76.5K	﹤0.01%	744
2015 Q4	$466K	Sell	4,451 -74	-2%	-$7.73K	﹤0.01%	706
2015 Q3	$477K	Buy	4,525 +2,060	+84%	+$275K	﹤0.01%	700
2015 Q2	$337K	Sell	2,465 -3,483	-59%	-$432K	﹤0.01%	714
2015 Q1	$741K	Sell	5,948 -815	-12%	-$86.4K	﹤0.01%	609
2014 Q4	$611K	Sell	6,763 -386	-5%	-$32.1K	﹤0.01%	649
2014 Q3	$516K	Buy	7,149 +335	+5%	+$22K	﹤0.01%	662
2014 Q2	$424K	Buy	6,814 +1,759	+35%	+$106K	﹤0.01%	713
2014 Q1	$345K	Buy	+5,055	New	+$373K	﹤0.01%	756

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brown Advisory's BMRN Position: Q2 2026 in Review

Brown Advisory opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 9,087 shares worth $520K. The stake represents ﹤0.01% of the portfolio and ranks #1127 among its holdings. This is a return to the name: Brown Advisory previously reported a position in BMRN as recently as Q4 2017.

Brown Advisory first reported a position in BMRN in Q1 2014 and has held it in 17 quarters since. The position peaked at $1.06M in Q2 2016. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Brown Advisory held 9,087 shares of BioMarin Pharmaceuticals worth $520K as of Q2 2026.
BioMarin Pharmaceuticals was a new Brown Advisory position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1127 holding.
Brown Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 17 quarters since.
Brown Advisory's BioMarin Pharmaceuticals position peaked at $1.06M in Q2 2016.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.